Med. Pro Praxi 2009; 6(2): 77-81

Dietary supplements in clinical practice

doc. MUDr. Eliška Sovová Ph.D., MBA
I. interní klinika FN a LF UP Olomouc

Optimal nutrition with the right proportion of essential nutrients (proteins, saccharides, and fats) and adequate amount of vitamins,

minerals, and other antioxidants is the cornerstone of prevention of all civilization diseases. Antioxidants contained in food decrease the

occurrence of both cardiovascular and cancerous diseases. No study has confirmed a positive effect of vitamin supplementation (vitamin

C, vitamin E, folic acid) in tablet form in the prevention of civilization diseases. Vitamin and mineral supplementation can be recommended

in the case of deficiency or when there is an increased demand for them. Other substances for which studies are available that

attempt to confirm the appropriateness of their use in particular diseases include carnitine, creatine, arginine, taurine, lecitin, omega-3

polyunsaturated fatty acids, vegetable sterols, and coenzyme Q 10. Using evidence-based medicine (EBM), the level of recommendation

is I A for omega-3 polyunsaturated fatty acids (there is EBM or general expert consensus that treatment is beneficial and data are derived

from at least two randomized studies that confirm the efficacy of treatment). For vegetable sterols, the level of recommendation is I C

(there is general expert consensus based on smaller studies).

Keywords: dietary supplements, carnitine, creatine, arginine, taurine, coenzyme Q 10, lecitin, omega-3 polyunsaturated fatty acids, vegetable sterols.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sovová E. Dietary supplements in clinical practice. Med. praxi. 2009;6(2):77-81.
Download citation

References

  1. Goumas G, Tentolouris C, Tousoulis D, et al. Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 2001; 154. 255-267. Go to original source... Go to PubMed...
  2. Leman A, Burnett JC, Gitano ST, et al. Long term L-arginin supplementation improves small vessel coronary endothelial function in humans. Circulation 1998; 97: 2123-2128. Go to original source... Go to PubMed...
  3. Suzuki T, Hayase M, Hibi K, et al. Effects of local delivery of L- arginin on in stent restenosis in humans. Am J Cardiol 2002; 89: 363-367. Go to original source... Go to PubMed...
  4. Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 2002; 39: 1199-2003. Go to original source... Go to PubMed...
  5. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002; 86: 317-323. Go to original source... Go to PubMed...
  6. Lim D, Mooradian S, Goldberg C, et al. Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. Am J Cardiol 2004; 94(6): 828-831. Go to original source... Go to PubMed...
  7. Boccchi EA, Morales AV, Esteves-Filho A, et al. L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol 2000; 23: 205-210. Go to original source... Go to PubMed...
  8. Wilson AM, Harada R, Nair N, et al. L arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007; 116(2): 188-195. Go to original source... Go to PubMed...
  9. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64. Go to original source... Go to PubMed...
  10. Boger RH. L-arginine therapy in cardiovascular pathologies: beneficial or dangerous. Curr Opin Nutr Metab Care 2008; 11(1): 55-61. Go to original source... Go to PubMed...
  11. Evans R, Fernstrom R, Thompson J, et al. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. Journal of Nutritional Biochemistry, 2004; 15(9): 534-539. Go to original source... Go to PubMed...
  12. Ferrari R, Merli E, Cicchitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L- carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91. Go to original source... Go to PubMed...
  13. Safi AM, Samala CA, Stein RA. Role of nutriceutical agents in cardiovascular diseases: update-part II. Cardiovasc Rev Rep 2003; 24(8): 405-412.
  14. Iliceto S, Scrutinio D, Bruzzi P, et al. Effect of L carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L carnitine ecocardiografia digitalizzata infarto miocardico (CEDIM) trial. J Am Coll Cardiol 1995; 26: 380-387. Go to original source... Go to PubMed...
  15. Lango R, Smolenski RT, Rogowsk J, et al. Propionyl L carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther 2005; 19(4): 267-275. Go to original source... Go to PubMed...
  16. Allard ML, Jeejeebhoy KN. The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 2006; 11(1): 75-82. Go to original source... Go to PubMed...
  17. De Giuli F, Pasini E, Opasich C, et al. Effects of propionyl L carnitine in patients with heart failure. J Mol Cell Cardiol 1995; 27: V44.
  18. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992; 42: 1101-1104.
  19. Sayed-Ahmed MM, Salman TM, Gaballah HE, et al. Propionyl L carnitine as protector against adriamycin induced cardiomyopathy. Pharmacol Res 2001; 43(6): 513-520. Go to original source... Go to PubMed...
  20. El-Beshlawy A, Ragab L, Fattah AA, et al. Improvement of cardiac function in thalassemia major treated with L carnitine. Acta Haematol 2004; 111(3): 143-148. Go to original source... Go to PubMed...
  21. Kazmi WH, Obrador GT, Sternberg M, et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. Am J Nephrol 2005; 25(2): 106-115. Go to original source... Go to PubMed...
  22. Dhanasekaran M, Ren J. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovasc Res 2005; 2(5): 447-459. Go to original source... Go to PubMed...
  23. Baggio E, Gandini R, Placher AC, et al. Italian multicenter study on safety and efficacy of coenzyme Q 10. Mol Aspects Med 1994; 15: 287-294. Go to original source... Go to PubMed...
  24. Witte KK, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality of life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005; 26: 2238-2244. Go to original source... Go to PubMed...
  25. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analysis of clinical trials. Mol Aspects Med 1997; 18(suppl.): 159-168. Go to original source... Go to PubMed...
  26. Rosenfeldt F, Hilton D, Pepe S, et al. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003; 18: 91-100. Go to original source... Go to PubMed...
  27. Muller T, Buttner T, Gholipour AF, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003; 341: 201-204. Go to original source... Go to PubMed...
  28. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 137-141. Go to original source... Go to PubMed...
  29. Volek JS, Rawson ES. Scientific basis and practical aspects of creatine supplementation for athletes. Nutrition 2004; 20(7-8): 609-614. Go to original source... Go to PubMed...
  30. Kley RA, Vorgerd M, Tarnopolsky MA. Creatine for treating muscle disorders. Cochrane Database Syst Rew 2007; (1): CD004760. Go to original source...
  31. Andrews R, Greenhaff P, Curtis S, et al. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 1998; 19: 617-622. Go to original source... Go to PubMed...
  32. Gordon A, Hultman E, Kaijser L, et al. Creatine supplementation in chronic heart failure increases skeletal muscle creatin phosphate and muscle performance. Cardiovasc Res 1995; 30: 413-418. Go to original source... Go to PubMed...
  33. Mastellone I, Polichetti E, Gres S, et al. Dietary soybean phosphatidylcholines lower lipidemia: mechanisms at the levels of intestine, endothelial cell, and hepato-biliary axis. J Nutr Biochem 2000; 11(9): 461-466. Go to original source... Go to PubMed...
  34. Risti M, Risti V, Arsi A, et al. Efffects of soyabean D-LeciVita product on serum lipids and fatty acid composition in type 2 diabetic patients with hyperlipidemia. Nutr Metab Cardiovasc Dis 2006; 16(6): 395-404. Go to original source... Go to PubMed...
  35. Simopoulos AP. Omega 3 fatty acids in the prevention management of cardiovascular disease. Can J Physiol Pharmacol 1997; 75: 234-239. Go to original source...
  36. Škottová N, Ulrichová J, Křen V, a kol. Flavonoidy silymarinu a polynenasycené mastné kyseliny rybízového oleje jako nutraceutikum v prevenci chronických onemocnění. Prakt Lék 2003; 83(8): 444-456.
  37. Kraml P. Hyperlipoproteinemie v klinické praxi. Horizonty diabetologie díl 3. Tigis, 2008.
  38. Burr ML, Fehily AM, Gilbert LF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-761. Go to original source... Go to PubMed...
  39. Gissi-prevenzione investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet 1999; 354: 447-455. Go to original source...
  40. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eikosapentaenoic acid on major events in hypercholesterolaemic patients (JELIS). a randomised open label blinded endpoint analysis. Lancet 2007; 369: 1090-1098. Go to original source... Go to PubMed...
  41. Sovová E. Nutriční doplňky v kardiologii. Které máme svým pacientům doporučit? Praktický lékař 2007; 87(7): 391-394.
  42. Christensen JH, Riahi S, Schmidt EB, et al. N-3 fatty acids and ventricular arrhytmias in patients with ischaemic heart disease and implantable defibrillators. Europace 2005; 7: 338-344. Go to original source... Go to PubMed...
  43. Mozaffarian D, Geelen A, Brouwer IA, et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005; 112: 1945-1952. Go to original source... Go to PubMed...
  44. Calo L, Bianconi L, Colivicchi F, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary bypass surgery. J Am Coll Cardiol 2005; 45: 1723-1728. Go to original source... Go to PubMed...
  45. Jenkins DJ, Josse AR, Beyene J, et al. Fish oil supplementation with implantable cardioverter defibrilators: A meta analysis. CMAJ 2008; 178: 157-164. Go to original source... Go to PubMed...
  46. Zatsick NM, Mayket P. Fish oil: getting to the heart of it. J Nurs Pract 2007; 3: 104-109. Go to original source...
  47. Informace vědeckého výboru pro potraviny ve věci: fytosteroly v potravinách nového typu (PNT). Státní zdravotní ústav Brno. Dostupné na www.chpr.szu.cz/vedvybor/vvp.htm.
  48. Law M. Plant sterol and stanol margarines and health. British Med J 2000; 320: 1-4. Go to original source... Go to PubMed...
  49. Blair SN, Capuzzi DM, Gottlieb SO, et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000; 84: 46-52. Go to original source... Go to PubMed...
  50. Modrianský M, Valentová K, Přikrylová V, et al. Přírodní látky v prevenci onemocnění trávícího traktu. Chem listy 2003; 97: 540-547.
  51. Demonty I, Ebine N, Kia X, et al. Fish oil fatty acid esters of phytosterols alter plasma lipids but not red blood cell fragility in hamsters. Lipid 2005; 40: 695-752. Go to original source... Go to PubMed...
  52. Demonty I, Chan YM, Pelled D, et al. Fish-oil esters of plant sterols improve the lipid profile of dylipidemic subjects more than do fish-oil sunflower oil esters of plant sterols. Am J Clin Nutr, 2006; 84: 1534-1542. Go to original source... Go to PubMed...
  53. Satoh H. Cardioprotective actions of taurine against intracellular and extracellular calcium-induced effects. Adv Exp Med Biol 1994; 359: 181-196. Go to original source... Go to PubMed...
  54. Sperelakis N, Satoh H, Bkaily G. Taurine effects on ionic currents in myocardial cells. Adv Exp Med Biol 1992; 315: 129-143. Go to original source... Go to PubMed...
  55. Azuma J, Sawamura A, Awata N, et al. Usefulness of taurine in chronic heart failure and its prospective application. Jpn Circ J 1992; 56: 95-99. Go to original source... Go to PubMed...
  56. Jeejeebhoy F, Keith M, Freeman M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 2002; 143: 1092-1100. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.